NLRP3 and metabolic dysfunction-associated steatotic liver disease: Wang et al.’s research revealed that naringenin hindered the onset of nonalcoholic fatty liver disease (NAFLD) by suppressing NLRP3 inflammasome activation, preventing Caspase-1 lysis, and mitigating liver inflammation in mice [58].